article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. FDA and Japan’s Pharmaceuticals and Medical Device Agency (PMDA) on the proposed design of the Phase 3 clinical trial. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

Medical Grade Skincare vs. Over-the-Counter Products: What’s the Difference?

Kim Gallo Esthetics

Also known as pharmaceutical-grade , medical-grade skincare is exactly what it sounds like - products that are both developed and tested by medical professionals. FDA regulated Medical-grade skincare products are regulated by the FDA to ensure they meet safety and quality standards. What is medical-grade skincare?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.

article thumbnail

Last Patient Dosed in Part 2 of Verrica’s Phase 2 Study of VP-315 in BCC 

The Dermatology Digest

The last patient has been dosed in Part 2 of Verrica Pharmaceuticals Inc.’s The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 in adults with biopsy-proven basal cell carcinoma.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

“It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.”

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

article thumbnail

Biosimilar Watch: FDA Accepts BLA for Proposed Stelara Biosimilar 

The Dermatology Digest

The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy. As a global subsidiary of Intas Pharmaceuticals, Accord BioPharma will be responsible for U.S. commercialization.